Abstract

Mini Review

Challenge of polymers for biosimilar products packaging

Anupam Chanda*

Published: 29 September, 2021 | Volume 5 - Issue 1 | Pages: 057-058

Presently Packaging plays a significant role for Biosimilar product. The process of selecting materials and the type of packaging also offers an opportunity for the Packaging scientist to look for new biological delivery choices. Most injectable protein products were supplied in some sort of glass vial, prefilled syringe, and cartridge. Those product having high Ph content there is a chance of “delamination “from inner surface of glass vial. With protein-based drugs, the biggest issue is the effect of packaging derivatives on the protein’s three-dimensional and surface structure. These are any effects that relate to denaturation or aggregation of the protein due to oxidation or interactions from contaminants or impurities in the preparation. The potential for these effects needs to be carefully considered in choosing the container and the container closure system to avoid putting patients in jeopardy.

Read Full Article HTML DOI: 10.29328/journal.abb.1001029 Cite this Article Read Full Article PDF

References

  1. Mei-Yue W, Zhao R, Li-Juan G, Xue-Fei G, De-Ping W, et al. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front Cell Infect Microbiol. 2020; 10: 587269. PubMed: https://pubmed.ncbi.nlm.nih.gov/33324574/
  2. Pirone L, Del Gatto A, Di Gaetano S, Saviano M, Capasso D, et al. A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment. Front Mol Biosci. 2020; 7: 186. PubMed: https://pubmed.ncbi.nlm.nih.gov/32850973/
  3. Luan J, Lu Y, Gao S, Zhang L. A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2. 2020; 81: 318-356. PubMed: https://pubmed.ncbi.nlm.nih.gov/32283163/
  4. Calver J, Joseph C, John AE, Organ L, Fainberg H, et al. Understanding lung infection: back to basics. S31 The novel coronavirus SARS-CoV-2 binds RGD integrins and upregulates avb3 integrins in Covid-19 infected lungs. Thorax BMJ. 2021; 76: A22-A23.
  5. Zhang S, Liu Y, Wang X, Yang L, Li H, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol. 2020; 13: 120. PubMed: https://pubmed.ncbi.nlm.nih.gov/32887634/
  6. Allegra A, Innao V, Allegra AG, Musolino C. Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies. Ann Hematol. 2020; 99: 1953-1965. PubMed: https://pubmed.ncbi.nlm.nih.gov/32671455/
  7. Liu Y, Yang Y, Zhang C, Huang F, Wang F, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020; 63: 364-374. PubMed: https://pubmed.ncbi.nlm.nih.gov/32048163/
  8. Smadja DM, Qun-Ying Y, Chocron R, Sanchez O, Louet AL. Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase. Eur Respir J. 2021; PubMed: https://pubmed.ncbi.nlm.nih.gov/33863748/
  9. Loo KY, Letchumanan V, Ser HL, Teoh SL, Law JWF, et al. COVID-19: Insights into Potential Vaccines. Microorganisms. 2021; 9: 605. PubMed: https://pubmed.ncbi.nlm.nih.gov/33804162/
  10. Grobbelaar LM, Venter C, Vlok M, Ngoepe M, Laubsche GJ, et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19. 2021.

Figures:

Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More